Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14880059 | 0.98 | LMNA (0.36) | LMNACYP2C9HTR6KCNH2 | |
| SCHEMBL2292002 | 0.91 | HTR6 (0.42) | LMNACYP2C9HTR6KCNH2 | |
| SCHEMBL9595459 | 0.87 | LMNA (0.42) | LMNACYP2C9HTR2AHTR2C | |
| SCHEMBL272039 | 0.84 | — | — | |
| SCHEMBL16382274 | 0.84 | — | — | |
| SCHEMBL12029112 | 0.84 | — | — | |
| SCHEMBL12208387 | 0.84 | — | — | |
| SCHEMBL10690019 | 0.83 | — | — | |
| SCHEMBL31208679 | 0.82 | HTR6 (0.39) | LMNACYP2C9HTR6 | |
| Hydrochloric Acid SCHEMBL21378869 | 0.81 | LMNA (0.42) | LMNACYP2C9HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002367-A1 | BIFUNCTIONAL COMPOUNDS | C4 THERAPEUTICS, INC. | 2023-01-05 | — | — | US | disclosed |
| US-20200190175-A1 | METHOD FOR PREDICTING THERAPEUTIC EFFECT OF LSD1 INHIBITOR BASED ON EXPRESSION OF INSM1 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2020-06-18 | — | — | US | disclosed |
| US-10428034-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors | PFIZER INC. (US) | 2019-10-01 | — | — | US | disclosed |
| EP-3174879-B1 | SUBSTITUTED OXETANES AND THEIR USE AS INHIBITORS OF CATHEPSIN C | BOEHRINGER INGELHEIM INT (DE) | 2018-07-18 | — | — | EP | disclosed |
| US-20180065943-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | PFIZER INC. (US) | 2018-03-08 | — | — | US | disclosed |
| US-9663523-B2 | BET protein-inhibiting 5-aryltriazoleazepines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-05-30 | — | — | US | disclosed |
| US-9663523-B2 | BET protein-inhibiting 5-aryltriazoleazepines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-05-30 | — | — | US | disclosed |
| EP-2900672-B1 | BET-PROTEIN INHIBITORY 5-ARYL-TRIAZOLO-AZEPINES | Bayer Pharma AG (DE) | 2017-02-22 | — | — | EP | disclosed |
| US-20160129011-A1 | BICYCLO 2,3-BENZODIAZEPINES AND SPIROCYCLICALLY SUBSTITUTED 2,3-BENZODIAZEPINES | Bayer Pharma AG (DE) | 2016-05-12 | — | — | US | disclosed |
| US-20150299201-A1 | BET PROTEIN-INHIBITING 5-ARYL TRIAZOLE AZEPINES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-10-22 | — | — | US | disclosed |
| WO-2002030405-A2 | TREATMENT OF AFFECTIVE DISORDERS BY THE COMBINED ACTION OF A NICOTINIC RECEPTOR AGONIST AND A MONOAMINERGIC SUBSTANCE | NEUROSEARCH A/S (DK) | 2002-04-18 | — | — | WO | disclosed |
| US-20020037893-A1 | Heteroaryl diazabicycloalkanes, their preparation and use | ANIONA APS (DK) | 2002-03-28 | — | — | US | disclosed |
| EP-1177196-A1 | HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2002-02-06 | — | — | EP | disclosed |
| WO-2002002564-A1 | ARYL AND HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2002-01-10 | — | — | WO | disclosed |
| WO-2000066586-A1 | HETEROARYL DIAZABICYCLOALKANES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 2000-11-09 | — | — | WO | disclosed |
| US-5091383-A | SUBSTITUTED BRIDGED DIAZABICYCLOALKYL QUINOLONE CARBOXYLIC ACIDS | PFIZER INC. (US) | 1992-02-25 | — | — | US | disclosed |
| EP-0215650-B1 | SUBSTITUTED BRIDGED-DIAZABICYCLOALKYL QUINOLONE CARBOXYLIC ACIDS | PFIZER INC. (US) | 1992-01-29 | — | — | EP | disclosed |
| US-4861779-A | Anti-bacterial substituted bridged-diazabicycloalkyl quinolone carboxylic acids | PFIZER INC. (US) | 1989-08-29 | — | — | US | disclosed |
| US-4775668-A | Substituted bridged-diazabicycloalkyl quinolone carboxylic acids and anti-bacterial use thereof | PFIZER INC. (US) | 1988-10-04 | — | — | US | disclosed |
| EP-0215650-A2 | Substituted bridged-diazabicycloalkyl quinolone carboxylic acids | PFIZER INC. (US) | 1987-03-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160129011-A1 | BICYCLO 2,3-BENZODIAZEPINES AND SPIROCYCLICALLY SUBSTITUTED 2,3-BENZODIAZEPINES | BRD4, BRDT, BICRA | LMNA 1470/4885CYP2C9 2994/4885HTR6 2303/4885 |
| US-20200190175-A1 | METHOD FOR PREDICTING THERAPEUTIC EFFECT OF LSD1 INHIBITOR BASED ON EXPRESSION OF INSM1 | INMT, CARM1, KDM1B | LMNA 420/4885CYP2C9 3735/4885HTR6 1402/4885 |
| US-20020037893-A1 | Heteroaryl diazabicycloalkanes, their preparation and use | CHRNA5, CHRNA7, CHRNA2 | LMNA 2803/4885CYP2C9 992/4885HTR6 804/4885 |
| US-20150299201-A1 | BET PROTEIN-INHIBITING 5-ARYL TRIAZOLE AZEPINES | BRD4, BRDT, BET1 | LMNA 2586/4885CYP2C9 4458/4885HTR6 2391/4885 |
| US-20180065943-A1 | 1,1,1-TRIFLUORO-3-HYDROXYPROPAN-2-YL CARBAMATE DERIVATIVES AND 1,1,1-TRIFLUORO-4-HYDROXYBUTAN-2-YL CARBAMATE DERIVATIVES AS MAGL INHIBITORS | MAG, PYM1, HIF1AN | LMNA 2311/4885CYP2C9 1647/4885HTR6 443/4885 |
| US-20230002367-A1 | BIFUNCTIONAL COMPOUNDS | ITCH, EGFR, MUC1 | LMNA 4585/4885CYP2C9 967/4885HTR6 3747/4885 |
| US-10428034-B2 | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2-yl carbamate derivatives as MAGL inhibitors | MAG, PYM1, HIF1AN | LMNA 2311/4885CYP2C9 1647/4885HTR6 443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.